

EMA/603716/2015

European Medicines Agency decision

P/0221/2015

of 2 October 2015

on the agreement of a paediatric investigation plan and on the granting of a waiver for adenovirus associated viral vector serotype 2 containing the human RPE65 gene (EMEA-001684-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0221/2015

of 2 October 2015

on the agreement of a paediatric investigation plan and on the granting of a waiver for adenovirus associated viral vector serotype 2 containing the human RPE65 gene (EMA-001684-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Spark Therapeutics Inc on 11 August 2014 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 August 2015, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for adenovirus associated viral vector serotype 2 containing the human RPE65 gene, solution for injection, intraocular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for adenovirus associated viral vector serotype 2 containing the human RPE65 gene, solution for injection, intraocular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Spark Therapeutics Inc, 3737 Market Street, Suite 1300, PA 19104 – Philadelphia, United States.

Done at London, 2 October 2015

For the European Medicines Agency
Jordi Llinares Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/384694/2015
London, 14 August 2015

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMA-001684-PIP01-14

Scope of the application

Active substance(s):

Adenovirus associated viral vector serotype 2 containing the human RPE65 gene

Condition(s):

Treatment of genetic congenital retinal disorders

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Intraocular use

Name / corporate name of the PIP applicant:

Spark Therapeutics Inc

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Spark Therapeutics Inc submitted for agreement to the European Medicines Agency on 11 August 2014 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 14 October 2014.

Supplementary information was provided by the applicant on 26 May 2015. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of genetic congenital retinal disorders

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- solution for injection, intraocular use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of genetic congenital retinal disorders

2.1.1. Indication(s) targeted by the PIP

Treatment for inherited retinal degeneration due to autosomal-recessive RPE65 gene mutations

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.

Clinical studies	1	Study 1 Open-label, randomised, single dose, controlled trial to evaluate activity and safety of adenovirus associated viral vector serotype 2 containing the human RPE65 gene compared to no treatment in children from 3 to less than 18 years of age (and adults) with Leber's congenital amaurosis type 2.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By April 2015
Deferral for one or more measures contained in the paediatric investigation plan:	No